slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,578
Current window 100,921-100,950
Pages 3,953
Rows per page 30
Component
100,921-100,950 of 118,578
16
The slide outlines the randomization, treatment arms, timeline, patient population criteria, and primary/secondary endpoints.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
17
Uses a combination of an additive equation for the value prop and a chevron-based timeline for the life cycle management.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
19
The slide uses a matrix-like structure to map disease areas (Infection, Inflammation, Oncology) to specific animal models and clinical indications.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
20
Uses a chevron-based process flow to represent maturity stages.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
21
The chart shows dose-response curves where LNC formulations consistently outperform Taxol.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
23
The study is an ex-vivo human whole blood study using 80 ug/mL LNC and 512 ng/mL Cy5-labeled siRNA cargo.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
24
The slide compares LNC formulations against IMQ-only and IL-17A antibody controls.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
27
The slide uses a three-column icon-based layout to summarize key IP milestones.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
01
Matson | Results Presentation Deck | 10 slidesMatson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Attention1 hit
01
MaxCyte | Investor Presentation Deck | 21 slidesMaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations 1 hit
11
The chart uses a stacked bar format to distinguish between pre-commercial and commercial revenue components.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
16
The model is explicitly labeled as 'Razor/Razor Blade Economics'.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · Business Model1 hit
17
Uses the 'Razor/Razor Blade' business model framework.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · Business Model1 hit
21
MaxCyte | Investor Presentation Deck | 21 slidesMaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · The AskLoop · Why Now1 hit
11
Includes reconciliation table for Net Revenues and Pre-Tax Profit adjustments.Morgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · New Bliss1 hit
12
Standard financial disclosure page for Morgan Stanley investor presentation.Morgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · New Bliss1 hit
06
The slide uses a Gantt-style layout to map clinical phases to specific time periods.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Loop · Golden Circle1 hit
07
The slide uses a medical illustration of the liver to highlight the target organ.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
17
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of the hormone.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
18
The slide uses preclinical data to demonstrate efficacy superiority over a market-leading GLP-1 agonist.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
19
The slide uses three distinct chart types to demonstrate efficacy and metabolic impact.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
20
Includes definitions for MAD, SAD, PK, PD, FPFV, and LPLV.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
25
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations 1 hit
01
Features a 3D rendering of a synapse.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
04
The slide uses a standard pharmaceutical pipeline visualization (Discovery to NDA).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
05
Includes a personal testimonial/case study image of a patient (Shay) to humanize the disease.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Problem1 hit
08
Includes a process diagram for iPSC generation and two charts: a survival curve and a hazard ratio bar chart.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
22
The slide uses a series of blue blocks to represent different research pillars/methodologies within the PARADIGM trial.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
23
The slide uses a case study to validate the business model of combination therapies.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
25
The slide presents clinical biomarker data comparing control vs AD groups across 6 different markers, using Mann-Whitney U tests for significance.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit